Holen Sie sich die Stockscreener-App
17.15
5.80%
0.94
Handel nachbörslich:
17.15
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Chart overlay techniques for tracking Arcutis Biotherapeutics Inc.Weekly Trend Report & Consistent Income Trade Ideas - Newser
Using Ichimoku Cloud for Arcutis Biotherapeutics Inc. technicals2025 Market Trends & Verified Entry Point Signals - Newser
ranking arcutis biotherapeutics inc. among high performing stocks via toolsWatch List & Daily Market Momentum Tracking - Newser
Arcutis Biotherapeutics’ Use of Inducement Grants: Strategic Talent Retention or Market Signal? - AInvest
Is Arcutis Biotherapeutics Inc. a defensive stockJuly 2025 News Drivers & Daily Profit Focused Screening - خودرو بانک
Arcutis Biotherapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
What’s the outlook for Arcutis Biotherapeutics Inc.’s sector2025 Retail Activity & Risk Managed Investment Entry Signals - خودرو بانک
35,500 Restricted Stock Units: Arcutis Biotherapeutics Grants Equity Awards to New Immuno-Dermatology Team - Stock Titan
Relative strength of Arcutis Biotherapeutics Inc. in sector analysisDividend Hike & Growth Oriented Trading Recommendations - Newser
Long term hold vs stop loss in Arcutis Biotherapeutics Inc.Quarterly Profit Review & Consistent Profit Trading Strategies - Newser
Ranking Arcutis Biotherapeutics Inc. among high performing stocks via toolsWeekly Volume Report & Weekly Breakout Opportunity Watchlist - Newser
What are the risks of holding Arcutis Biotherapeutics Inc.2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - 강소기업뉴스
Is Arcutis Biotherapeutics Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Report & Stepwise Trade Signal Implementation - Newser
Arcutis Biotherapeutics Inc. stock retracement – recovery analysis2025 Analyst Calls & Entry Point Strategy Guides - Newser
August's FDA Focus: Approvals and pipeline updates in pediatrics - Contemporary Pediatrics
Why is Arcutis Biotherapeutics Inc. stock going upWeekly Profit Recap & Proven Capital Preservation Methods - خودرو بانک
What’s the beta of Arcutis Biotherapeutics Inc. stockJuly 2025 WrapUp & Capital Efficiency Focused Strategies - خودرو بانک
Arcutis seeks FDA approval for psoriasis cream for young children By Investing.com - Investing.com Australia
Live market analysis of Arcutis Biotherapeutics Inc.July 2025 Action & Technical Pattern Based Buy Signals - Newser
Will Arcutis Biotherapeutics Inc. continue its uptrend2025 Earnings Impact & Technical Analysis for Trade Confirmation - Newser
What are analysts’ price targets for Arcutis Biotherapeutics Inc.2025 Investor Takeaways & Daily Profit Maximizing Tips - خودرو بانک
Detecting support and resistance levels for Arcutis Biotherapeutics Inc.July 2025 Gainers & Low Drawdown Investment Strategies - Newser
Will Arcutis Biotherapeutics Inc. rebound enough to break evenPortfolio Value Summary & Verified Swing Trading Watchlist - Newser
What technical models suggest about Arcutis Biotherapeutics Inc.’s comeback2025 EndofYear Setup & Safe Swing Trade Setups - Newser
Chart based analysis of Arcutis Biotherapeutics Inc. trends2025 Earnings Impact & Capital Protection Trading Alerts - Newser
Will Arcutis Biotherapeutics Inc. bounce back from current supportMarket Volume Report & Free High Accuracy Swing Entry Alerts - Newser
When Can We Expect A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)? - 富途牛牛
Arcutis submits sNDA for roflumilast cream 0.3% for treatment of psoriasis in children 2-5 years - Contemporary Pediatrics
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight - GlobeNewswire Inc.
Arcutis Seeks Expanded Indication for Zoryve - MarketScreener
Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years - HCPLive
Arcutis seeks FDA approval for psoriasis cream for young children - Investing.com
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 - The Manila Times
Arcutis Biotherapeutics Submits Application for ZORYVE Cream as First Topical Treatment for Plaque Psoriasis in Children Ages 2 and Up - Quiver Quantitative
First-Ever PDE4 Inhibitor for Toddlers: Arcutis' ZORYVE Aims to Transform Psoriasis Treatment Ages 2-5 - Stock Titan
Developing predictive dashboards with Arcutis Biotherapeutics Inc. dataOil Prices & Weekly Watchlist of Top Performers - Newser
Former Arcutis CTO with 52 US Patents Joins Palvella Therapeutics to Expand Rare Skin Disease Platform - Stock Titan
Using Bollinger Bands to evaluate Arcutis Biotherapeutics Inc.July 2025 Big Picture & Step-by-Step Swing Trade Plans - Newser
What high frequency data says about Arcutis Biotherapeutics Inc.Trade Risk Summary & Stepwise Entry and Exit Trade Signals - Newser
What is Arcutis Biotherapeutics Inc. s 5 year growth outlookQuarterly Risk Review & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
Is Arcutis Biotherapeutics Inc. stock a smart retirement pick2025 Investor Takeaways & Real-Time Volume Spike Alerts - خودرو بانک
HCPLive 5 Stories in Under 5: Week of 08/24 - HCP Live
Can Arcutis Biotherapeutics Inc. sustain earnings growthMarket Weekly Review & Precise Entry and Exit Recommendations - خودرو بانک
Will Arcutis Biotherapeutics Inc. benefit from current market trendsEarnings Summary Report & Growth Oriented Trading Recommendations - خودرو بانک
Is Arcutis Biotherapeutics Inc. backed by strong institutional buyingJuly 2025 Retail & Reliable Entry Point Trade Alerts - خودرو بانک
Can Arcutis Biotherapeutics Inc. stock double in the next yearInsider Buying & Technical Analysis for Trade Confirmation - خودرو بانک
Is Arcutis Biotherapeutics Inc. stock showing strong momentum2025 Performance Recap & Low Drawdown Momentum Trade Ideas - خودرو بانک
Is Arcutis Biotherapeutics Inc. forming a bullish divergence2025 Buyback Activity & Proven Capital Preservation Methods - خودرو بانک
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect? - sharewise.com
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):